<?xml version="1.0" encoding="UTF-8"?>
<p id="Par64">In addition to this, a new class of anti-influenza drug "baloxavir marboxil" has recently been licensed for the management of both influenza A and B viruses, a mode of action of this drug achieved by inhibiting the endonucleases of the viral polymerase enzyme complex. Although studies have shown that this antiviral compound has a significantly higher effect than Oseltamivir but is only authorized for use in Japan and the USA [
 <xref ref-type="bibr" rid="CR96">96</xref>].
</p>
